KA101 outperforms other clinical adjuvants in inducing balanced Th1/Th2 immunity and robust B cell responses to varicella-zoster virus glycoprotein E - Top-Institutions - MDSpire

KA101 outperforms other clinical adjuvants in inducing balanced Th1/Th2 immunity and robust B cell responses to varicella-zoster virus glycoprotein E

  • By

  • Yaru Quan

  • Su Zhang

  • Wenwen Wang

  • Yiping Wang

  • Kangwei Xu

  • Kaiqin Wang

  • Wenyan Wan

  • Jiaojiao Nie

  • July 16, 2026

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    Emory University
    Emory University

    Atlanta, Georgia

    Key Differentiators

    • Immunology
    • Vaccinology

  • #2

    Mayo Clinic
    Mayo Clinic

    Rochester, Minnesota

    Key Differentiators

    • Immunology
    • Vaccinology

Original Source(s)

KA101 outperforms other clinical adjuvants in inducing balanced Th1/Th2 immunity and robust B cell responses to varicella-zoster virus glycoprotein E

  • by Yaru Quan, Su Zhang, Wenwen Wang, Yiping Wang, Kangwei Xu, Kaiqin Wang, Wenyan Wan, Jiaojiao Nie

  • July 16, 2026

Related Content

Intensive versus standard statin therapy in acute ischemic stroke: a comparative study on the risk of pneumonia and multidrug-resistant bacterial infections

Atypical subcutaneous nodule-type paragonimiasis in 3 children: case series

Differential tear metabolomics in blepharokeratoconjunctivitis and herpes simplex keratitis: potential biomarkers for clinical differentiation